SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis

Wojciech Płazak1, Leszek Drabik2,3

  • 1Department of Cardiac and Vascular Diseases, John Paul II Hospital, Jagiellonian University Medical College, Krakow, Poland. wplazak@szpitaljp2.krakow.pl.

Clinical Rheumatology
|January 9, 2023
PubMed

Insights

Systemic lupus erythematosus and COVID-19 share similar pathways, including endothelial dysfunction, increasing risks for atherosclerosis and thrombosis. Understanding these links aids in managing cardiovascular complications in both conditions.

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Infectious Diseases

Background:

  • Connective tissue diseases, like systemic lupus erythematosus (SLE), are linked to increased atherosclerotic and thrombotic risks due to endothelial dysfunction.
  • COVID-19 infection presents with hypercoagulable and hyperinflammatory states, sharing pathogenic mechanisms with rheumatic diseases.

Purpose of the Study:

  • To explore the shared pathophysiological mechanisms between SLE and COVID-19, focusing on endothelial dysfunction.
  • To discuss the implications for atherosclerosis and thrombosis in both conditions.
  • To highlight therapeutic strategies for improving endothelial function.

Main Methods:

  • Review of existing literature on SLE, COVID-19, endothelial dysfunction, atherosclerosis, and thrombosis.
  • Comparative analysis of pathogenic mechanisms in SLE and COVID-19.
  • Discussion of therapeutic interventions for endothelial dysfunction.

Main Results:

  • SLE and COVID-19 exhibit similar pathologies, including endothelial activation/dysfunction, complement system activation, antiphospholipid antibodies, and neutrophil extracellular traps.
  • Autoimmunity in both diseases contributes to hyperinflammation, hypercoagulability, hypofibrinolysis, and thromboembolic events.
  • Cardiovascular manifestations like coronary artery disease, stroke, and pulmonary embolism are associated with these shared mechanisms.

Conclusions:

  • Endothelial dysfunction is a central mechanism linking SLE and COVID-19, driving atherosclerosis and thrombosis.
  • Recognizing these pathophysiological similarities is crucial for managing cardiovascular risks in patients with SLE and post-COVID-19.
  • Targeting endothelial dysfunction may offer therapeutic benefits for preventing thromboembolic complications in both diseases.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
21
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
22
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
34
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
26
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
27